Official: Two Real Madrid announce sales of two players
La Liga giants Real Madrid have over the last 24 hours announced a pair of departures from the club's playing ranks.
This comes amid confirmation that both Rafael Obrador and Víctor Muñoz have moved on.
Advertisement
In the case of the former, the talented full-back has made the move to Portugal, putting pen to paper on terms with Benfica.
As per a statement across the website and social media platforms of Los Blancos, after the 21-year-old's name was brought to the fore in discussions over Real's deal for Álvaro Carreras:
'Real Madrid C.F. and Sport Lisboa e Benfica have reached an agreement for the transfer of our player Rafael Obrador.'
And joining Obrador in bidding farewell to Spain's capital is attacker Víctor Muñoz.
Winger Muñoz's name will likely be familiar to regular viewers of Real Madrid, after the 21-year-old racked up a number of first-team appearances over the final weeks of the recently-completed La Liga season, and at the Club World Cup.
Advertisement
In search of more consistent opportunities at senior level, though, Muñoz has this week signed with fellow Spanish top-flight outfit Osasuna:
'Real Madrid C. F. and C. A. Osasuna have reached an agreement for the transfer of our player Víctor Muñoz.'
Conor Laird – GSFN
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
37 minutes ago
- Yahoo
Is Novo Nordisk Stock a Buy, Sell, or Hold Before Q2 Earnings?
Danish pharmaceutical giant Novo Nordisk A/S (NVO) is facing serious headwinds. After enjoying a strong run fueled by demand for its obesity treatments, the obesity drug pioneer is now under pressure from rising competition, particularly from Eli Lilly's (LLY) weight-loss drugs, as well as trial setbacks for its next-generation therapies. In fact, things took a sharp turn on July 29, when the company cut its full-year sales growth guidance for the second time in just three months and named a new CEO. The market response was swift and brutal, with NVO shares plunging over 21% in a single day. Now, with second-quarter earnings just around the corner on Aug. 6, does Novo Nordisk's recent plunge present a golden buying opportunity, or is it a clear signal to keep your distance? More News from Barchart Dear Nvidia Stock Fans, Mark Your Calendars for August 27 Options Traders Expected Palantir Stock's Tamest Earnings Reaction in a Year. Did They Get It Right? Tesla Gains on Elon Musk's New Pay Package. Is TSLA Stock a Buy? Our exclusive Barchart Brief newsletter is your FREE midday guide to what's moving stocks, sectors, and investor sentiment - delivered right when you need the info most. Subscribe today! About Novo Nordisk Stock Best known for its blockbuster weight-loss drugs Ozempic and Wegovy, Novo Nordisk is a global healthcare leader with a long-standing focus on chronic disease. Founded in 1923 and headquartered in Denmark, the company has built a strong foundation in diabetes care while expanding its reach into obesity and other severe health conditions. The company commands a market capitalization of about $217.9 billion. While Novo Nordisk has been a trailblazer in the obesity drug market, its stock has hit a rough patch. Softer demand for its blockbuster drugs, combined with intensifying competition in the weight-loss space, has taken a toll on investor sentiment. The stock has tumbled a staggering 66% from its 52-week high of $139.74 reached in August 2024, and it's currently down 44.7% year-to-date (YTD). In stark contrast, the broader S&P 500 Index ($SPX) has managed to notch a gain of approximately 7.1% over the same period, while its rival Eli Lilly has seen only a marginal drop so far this year, highlighting just how far Novo has fallen out of favor with the market. Given its underwhelming price action, Novo Nordisk stock is starting to look like a value play. Currently trading at just 12.5 times forward earnings, it's priced well below the sector median of 16.87x, and dramatically lower than its own five-year average of 30.92x. Novo Nordisk's Q1 Earnings Snapshot In early May, Novo Nordisk posted a solid first-quarter earnings report for fiscal 2025, but the shine was dulled by a cautious outlook. Total revenue climbed 19% year-over-year (YOY) to 78.1 billion Danish kroner, powered by a massive 85% surge in Wegovy sales, which hit 17.4 billion Danish kroner. Ozempic also continued to perform, with sales rising 18% to 32.7 billion Danish kroner. Profits also impressed, with net profit climbing 14% to 29 billion Danish kroner, while operating profit increased 22% to 38.8 billion Danish kroner. But despite these promising numbers, Novo trimmed its full-year sales growth and operating profit growth guidance, citing 'lower-than-planned penetration of branded GLP-1 treatments in the US.' The company pointed to the growing presence of U.S. compounding pharmacies, which have been legally producing copycat versions of Wegovy and Ozempic under an FDA-approved exemption for addressing drug shortages. That growing parallel market has begun to chip away at Novo's momentum. On a more promising note, the company completed its REDEFINE 2 trial during the quarter, with its next-generation drug CagriSema delivering an impressive 15.7% weight loss in patients with obesity or overweight conditions and type 2 diabetes. Novo plans to file for its first regulatory approval in early 2026, potentially marking the next significant chapter in its obesity pipeline. Novo Nordisk Slashes Guidance Again and Names New CEO On July 29, Novo Nordisk held a conference call that left investors rattled, as it unveiled major leadership changes and another sharp downgrade to its 2025 financial outlook. The company slashed its full-year sales growth guidance to 8%-14%, down from the previously expected 13%-21%. Operating profit growth was also revised lower, now projected at 10%-16% compared to May's forecast of 16%-24%. The revised outlook sent a strong signal that Novo is bracing for a more challenging year ahead. A big part of the pressure comes from its obesity blockbuster, Wegovy. In its update, Novo pointed to several headwinds weighing on U.S. sales, including the continued rise of compounded GLP-1 knockoffs, slower-than-expected market expansion, and increasing competition. These challenges have clouded the outlook for one of Novo's key growth drivers, sparking concerns about whether the company can maintain its dominance in the rapidly growing weight-loss market. Adding to the uncertainty, Novo also announced a leadership shake-up. Maziar Mike Doustdar, the current EVP of international operations, will take over as CEO on Aug. 7, succeeding Lars Fruergaard Jørgensen, whose surprise resignation was announced in May. The transition comes at a pivotal moment, with the company under pressure to protect market share and reignite growth amid shifting dynamics in the obesity drug landscape. What Do Analysts Think About Novo Nordisk Stock? Despite all the swirling uncertainty, there's still a hint of optimism in the air. With Novo Nordisk set to unveil its Q2 earnings on Aug. 6 and a new CEO stepping in shortly after, Wall Street hasn't lost faith, with analysts leaning cautiously bullish, giving the stock a consensus rating of 'Moderate Buy' overall. Of the 19 analysts offering recommendations, seven advise a 'Strong Buy,' nine suggest a 'Hold,' one advocates a 'Moderate Sell,' and the remaining two maintain a 'Strong Sell.' NVO's average analyst price target of $71.75 suggests 47% potential upside from current levels. However, the Street-high target of $112 implies that shares can rally as much as 129.5% from current price levels. On the date of publication, Anushka Mukherji did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
Yahoo
37 minutes ago
- Yahoo
Why Novo Nordisk Stock Slipped Today
Key Points It was a double miss for the Wegovy maker in its second quarter. It's been hammered not only by competing licensed drugs, but it also has to contend with copycats. 10 stocks we like better than Novo Nordisk › Novo Nordisk (NYSE: NVO) stock imitated the company's leading product on Wednesday by slimming down in price. The Danish pharmaceutical's shares lost nearly 4% of their value following its latest earnings release, comparing unfavorably to the modest (0.7%) gain of the S&P 500 index. Still growing, but... Novo Nordisk, famous for its Wegovy obesity drug (and its sibling, diabetes treatment Ozempic), unveiled its first half and second quarter of 2025 figures early Wednesday morning. For the quarter, the company booked 76.9 billion Danish kroner ($11.9 billion) in revenue, which was up only marginally on a sequential basis, and 13% higher compared to the same period of 2024. Net income, meanwhile, was down from the previous quarter but up from the year-ago quarter. It rose by 32% year over year to 26.5 billion kroner ($4.1 billion), or 5.96 kroner ($0.92) per share. Both headline numbers missed the consensus analyst estimates, although not by much. Pundits tracking the company were modeling the equivalent of just under $12 billion for revenue, and $0.95 per share on the bottom line. Although Novo Nordisk continues to post double-digit increases thanks largely to Wegovy and Ozempic, it has been in the investor doghouse so far this month. That's because at the end of July, it significantly cut its guidance for both total sales and operating profit. Withering competition Much of this has to do with the intense competition Novo Nordisk is facing due to the runaway success of those medications. These days, pharmacy sector powerhouse Eli Lilly is doing brisk business with a directly competing product, Zepbound, while third parties are copying Wegovy's semaglutide molecule for their own compounded products. The company announced no fewer than 14 new lawsuits on Tuesday, making a total of 146 across 40 U.S. states, to combat the latter. Should you invest $1,000 in Novo Nordisk right now? Before you buy stock in Novo Nordisk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Novo Nordisk wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $619,036!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,092,648!* Now, it's worth noting Stock Advisor's total average return is 1,026% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. Why Novo Nordisk Stock Slipped Today was originally published by The Motley Fool
Yahoo
43 minutes ago
- Yahoo
As Europe pushes towards its €1.5 trillion renewables target, companies like Ikea look for green power opportunities today
Swedish megabrand Ikea's affordable self-assembly furniture has made Scandi style the go-to look for homes, hotels and Airbnbs all over Europe. More than 30 million of its ubiquitous Poang armchairs, for example—curious-but-memorable names also being an Ikea speciality)—have been sold since launch in 1977, making it one of the most popular furniture products ever. But the company has another, less well-known claim to fame. Since 2009 it has invested over €4.2 billion ($4.9 billion) in renewable energy, which now provides 75% of the electricity used by the business to make, transport and retail all that furniture. 'Today, it turns out that we are also a mid-sized utility company, although to be honest that was not part of the strategy,' deadpans Jesper Brodin, CEO of Ingka (the largest Ikea franchisee, responsible for 90% of group sales). It's only half a joke: if their output was sold on the power market, the 49 wind farms and 26 solar parks owned by Ingka do produce enough low carbon electricity to meet the needs of 1.47 million EU households. The investment has certainly paid off in carbon terms. The firm's CO2 emissions—scope 1,2 and 3—are down 30% since the Paris Agreement of 2015, while sales have grown by 24% over the same period. Yet what started out as a desire to do the right thing for the planet and the brand (68% of Ikea customers think that climate change is the most serious global challenge, says Brodin) has morphed into an unexpected source of competitive advantage. $4.9 billion 'When we set out to invest, we were not sure that it would be smart from an economic point of view. But our energy bills are down 27% [from 2015] so we have saved a lot of money. Over a three-to-five-year period, renewables come out at about half the price [of fossil fuel generated power]. People think that renewable energy will come at a financial premium, but actually it's the opposite.' After the Russian invasion of Ukraine caused a two-year spike in wholesale gas prices, a similar change of emphasis has occurred in Brussels. The EU Commission's latest plan for its carbon economy—the Clean Industrial Deal, announced in February—has dropped previous appeals to the collective consciences of business leaders to help save the planet, in favor of focusing on the competitiveness advantages of further adopting renewable power across the continent. Commission president Ursula von der Leyen has said that the deal will 'cut the ties that still hold our companies back, and make a clear business case for Europe'. Alongside reforms to electricity and gas markets designed to cut energy costs, the Clean Industrial Deal aims to mobilize €100 billion of EU funding to support low-carbon manufacturing, particularly in hard-to-abate industries like metals, chemicals and cement that rely on hydrocarbons for their highly energy-intensive processes. The Commission predicts the policy program will create over 500,000 new jobs, and ample opportunities for European businesses looking to carve a competitive, low-carbon niche. Green steel start-up Stegra is one such company. It has raised a total of €6.5 billion (including a €250 million grant from the EU innovation fund) to build a plant at Boden in the north of Sweden which will use 100% renewable energy to produce 5 million tonnes of homegrown 'green' steel per annum by 2030, with a carbon footprint 95% smaller than a traditional 'brown' steel plant. Stegra's process uses renewable power to generate hydrogen, which is then used not as a fuel but as a chemical reagent. Production will begin at a lower level in 2026, and despite a 25%-30% price premium over brown steel, it is already proving popular: the firm has forward-sold around 1.25 million tonnes—half of its initial production target—to customers eager to get in on the green steel ground floor. 'Our customers are planning ahead, they see that brown steel will eventually be more expensive than green steel once the full cost of carbon is included. They are not buying it for branding or marketing purposes, it's pure economics,' says Henrik Henriksson, Stegra's CEO. High costs, big barriers If von der Leyen's vision of secure, green growth is to be realized at scale for more companies, Europe needs to ramp up the transition to renewables significantly, at the same time as bringing down costs. By the end of 2023, Europe (excluding Russia) had 786 gigawatts of installed renewable generation capacity, according to the International Renewable Energy Agency (IRENA). That's an increase of 79% since 2014, and the pace has continued since, with a record increase of 65.6 gigawatts in the EU alone last year and another record predicted this year. However, it still leaves a long way to go to reach the EU's ambitious targets of 69% of electricity consumption and 42.5% of total energy coming from renewables by 2030. According to the European Commission's 2022 REPowerEU plan to end reliance on Russian fossil fuels, the EU would need to nearly double its capacity to 1,236 gigawatts to achieve this goal. Some estimates suggest this will cost around €1.5 trillion. Then there's the need to update Europe's grids, not just to handle the greater peak loads from these investments, but also to cover the distance between the best sites for renewable generation (solar in southern Europe, wind in coastal western Europe) and distant urban centers. So far, network investment has considerably lagged investments in renewables themselves. 'Because of the variability of wind [and solar], there is an urgent need for more interconnectors, and more investment in grids,' says Christophe Zipf, spokesperson for WindEurope, the trade body for the EU wind energy industry. One such mooted project is the North Sea Renewables Grid, a £20bn project to link 400 wind turbines in the North Sea, to facilitate the exchange of wind power between countries on both sides of the water. 'Where there are such clusters it makes sense to link them to more than one country—the U.K., Denmark and Belgium for example,' Zipf says. But where will the money come from? Given the right regulatory environment, there is capital ready to move, says Francecso Starace, partner at EQT, the world's third largest private equity investor, which has invested €17 billion in renewables in Europe over the past 15 years. There is already quite an appetite for investment in the grid and distribution networks. The networks need to be restructured for the modern world, not for the world of 50 years ago when they were built. 'Regulators have a major role to play, but they need to understand that more money needs to be invested into the networks. Network operators need regulation that incentivizes investment rather than discouraging them from doing that, which has been the case for many years,' says Starace, a former CEO of Enel. In practice, pro-investment regulation can mean several things: improvements in investor returns, relaxation of planning restrictions and greater central coordination of national transmission upgrade schemes. Even if all that happens, what of the days when the sun isn't shining and the wind isn't blowing? Renewables may be homegrown, but their output is inherently unpredictable. 'Network operators need regulation that incentivizes investment rather than discouraging them from doing that, which has been the case for many years' As a result, Starace believes the next big thing will be grid-scale battery storage. 'We believe batteries will be the next source of explosive growth. Battery storage can deal with fluctuations, and batteries are becoming pervasively competitive and a compelling investment.' Battery infrastructure on this scale would also require substantial capital, of course, altogether making the idea of cheaper power by 2030 seem rather less likely: whether through bills or taxes, someone's got to pay. But relying on fickle global gas markets no longer seems an option once your main supplier turns into an adversary, and in the long term the economic logic is there: once the infrastructure is built, the marginal unit cost of renewable power is far lower. In the meantime, as companies like Ikea and Stegra are showing, European businesses are increasingly looking for opportunities from the transition itself, rather than just waiting for the light at the end of the tunnel. This story was originally featured on 登入存取你的投資組合
